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ABSTRACT  
Background and aims: Nicotinamide phosphoribosyltransferase (NAMPT) is an adipokine with 
physiological effects on the control of glucose homeostasis as well as potentially involved in 
inflammation. The association of circulating NAMPT concentrations with obesity has not been clearly 
established. The aim of the present work was to evaluate the effect of obesity on circulating 
concentrations and gene expression levels of NAMPT in human peripheral blood cells (PBCs) as well 
as its involvement in inflammation, glucose and lipid metabolism. 
Methods and results: Forty-four serum samples obtained from 14 lean and 30 obese volunteers were used 
to analyse the circulating concentrations of NAMPT. In addition, PBC, omental adipose tissue (OM) and 
liver biopsy samples obtained from a subgroup of subjects were used to determine transcript levels of 
NAMPT by Real-time PCR. Glucose and lipid profile as well as several inflammatory factors and hepatic 
enzymes were analysed. NAMPT circulating concentrations (P < 0.01) and gene expression levels in PBC 
(P < 0.05) were significantly increased in obese patients as compared to lean subjects. Total-cholesterol (P 
= 0.016), HDL-cholesterol (P = 0.036) and triglycerides (P = 0.050) were significant and independent 
determinants of circulating concentrations of NAMPT (P < 0.01). Moreover, a positive correlation (P < 
0.01) was found with the hepatic enzymes alanine aminotransferase, aspartate aminotransferase, and y-
glutamyltransferase after BMI adjustment. 
 
Conclusion: Our work shows that NAMPT circulating concentrations and mRNA expression levels in 
PBC are increased in obese patients and that plasma NAMPT levels are related to inflammation, lipid 
metabolism and hepatic enzymes suggesting a potential involvement in fatty liver disease and in the 
obesity-associated inflammatory state. 
*Corresponding author at: Department of Endocrinology, Clínica Universitaria de 
Navarra, University of Navarra, Avda. Pío XII, 36, 31008 Pamplona, Spain. Tel.: þ34 948 
25 54 00x4484; fax: þ34 948 29 65 00. E-mail address: gfruhbeck@unav.es (G. 
Frühbeck).
INTRODUCTION 
The incidence of obesity has dramatically increased in the last decades with excess adiposity being 
associated with the increased risk of type 2 diabetes mellitus (T2DM) [1], cardiovascular diseases 
[2], and negative effects on liver function [3]. Adipose tissue contributes to regulating whole-body 
metabolism as well as inflammatory and immune responses through the direct effects of adipokines 
[4-6]. 
In the past years, a rate-limiting component of the mammalian NAD biosynthesis pathway 
from nicotinamide called nicotinamide phosphoribosyltransferase (NAMPT) has emerged as a 
new adipokine [7-10]. NAMPT was first identified as pre-B cell colony-enhancing factor 
(PBEF), a highly conserved 52 kDa cytokine-like protein that enhances the maturation of B cell 
precursors in the presence of interleukin (IL)-7 and stem cell factor [11] and inhibits the 
apoptosis of neutrophils [12]. NAMPT, also named visfatin, has been also identified as a visceral 
fatderived adipokine with insulin-mimetic effects by binding to and activating the insulin 
receptor [13]. However, the physiological relevance of NAMPT remains controversial [13-18]. 
Although increased expression of NAMPT by visceral fat has been described [13], other studies 
failed to confirm the original finding and no differences were detected between both depots 
[14,19]. Moreover, whereas some investigators have reported higher plasma visfatin in 
individuals with obesity [14,20] and T2DM [21,22], other studies have shown opposite findings 
[23 25]. Revollo et al. [16] were unable to reproduce the insulin-mimetic activity of this protein, 
but a significant physiological role in the regulation of b-cell function through the NAD 
biosynthetic activity was detected, suggesting an important role of NAMPT in the control of 
glucose metabolism. 
Obesity is closely linked to systemic inflammation [26]. A new functional link between NAD 
metabolism and inflammation has been reported, suggesting a potential role for NAD-dependent 
enzymes in the regulation of proinflammatory cytokine production [27]. Furthermore, NAMPT 
was found to be predominantly produced and released by the adipose tissue-derived macrophages 
[28]. The reported association between NAMPT and inflammatory markers raises the possibility 
of inflammatory properties of NAMPT [29-32]. NAMPT has been shown to upregulate IL-6, IL-
1b and tumour necrosis factor (TNF) a in human monocytes [30]. It has been proposed that 
inflammation in adipose tissue in the obese state is a response to hypoxia in enlarged adipocytes 
distant from the vasculature [33]. In this sense, obesity has been associated with the formation of 
hypoxic areas within the fat tissue [34,35] with hypoxia-inducible factor-1-a (HIF1 a) being 
recognised as an important and well-characterized key regulator of the adaptive response to low 
oxygen tension [36]. Although the inflammatory response is mainly evident in the visceral 
adipose tissue in the presence of obesity, recent studies indicate that circulating mononuclear 
cells obtained from obese individuals are in a pro-inflammatory state, being also involved in the 
increased concentrations of inflammatory cytokines [37-40]. 
In this study we assessed the influence of obesity on circulating concentrations of NAMPT as 
well as its gene expression levels in human peripheral blood cells, a type of cells easily 
accessible and representative of the obesity-associated low-grade chronic inflammation. We 
also assessed the possible relevance of NAMPT in inflammation, glucose and lipid metabolism 
in a well-characterized group of subjects including lean and obese patients. 
 
METHODS 
For detailed Research Design and Methods see Supplementary Research Design and Methods. 
Patient selection 
In order to analyse the effects of obesity on plasma NAMPT concentrations, 44 volunteers [14 
lean (LN) and 30 obese (OB)] were recruited from healthy individuals and patients attending the 
Departments of Endocrinology and Surgery of the Clínica Universidad de Navarra. Patients were 
classified as obese according to both body mass index (BMI > 30 kg/m2) and body fat percentage 
(BF > 25% for males and BF > 35% for females). BMI was calculated as weight in kilograms 
divided by the square of height in meters and body fat was estimated by air-displacement-
plethysmography (Bod-Podo, Life Measurements, Concord, CA) [41]. Waist-to-hip ratio (WHR) 
was measured as the ratio between the circumference of the waist (at a midway level between the 
margin of the lowest rib and the iliac crest) and the hip (at the widest trochanters). 
Normoglycaemia (NG) and T2DM are defined following the criteria of the Expert Committee on 
the Diagnosis and Classification of Diabetes Mellitus based on both fasting plasma glucose 
concentrations and 2 h after an oral glucose tolerance test (OGTT) [42]. T2DM subjects were not 
on insulin therapy or on medication likely to influence endogenous insulin levels. 
 
 
In addition, gene expression levels of NAMPT and HIF1 « in peripheral blood cells (PBC) (n = 
26), omental adipose tissue (n = 23) and hepatic biopsies (n = 11) were assessed in a subgroup of 
subjects. While an intraoperative liver biopsy was performed in the obese patients undergoing 
bariatric surgery to obtain a histological diagnosis of the liver state, this procedure is not clinically 
justified in lean subjects. 
The study was approved, from an ethical and scientific standpoint, by the Hospital’s Ethical 
Committee (Comitéde Ética de la Investigación de la Universidad de Navarra) responsible for research 
and the written informed consent of participants was obtained. 
 
 
Blood assays 
Biochemical assays of subjects included in the study were measured as previously described [43]. 
Intra- and interassay coefficients of variation were 5.0 and 4.5%, respectively. NAMPT levels were 
assessed using a commercially available ELISA kit (ALPCO Diagnostics, Salem, NH, USA) 
according to the manufacturer’s instructions, being the intra- and inter-assay coefficients of 
variation of 4.3 and 7.6%, respectively. 
 
RNA extraction and real-time PCR 
The transcript levels for NAMPT and HIF1-« were quantified by Real-Time PCR (7300 Real-Time 
PCR System, Applied Biosystem, Foster City, CA, USA) as previously described [43]. Primers and 
probes (Supplementary Table 1) were designed using the software Primer Express 2.0 (Applied 
Biosystems). 
 
Statistical analysis 
Data are presented as mean ± standard deviation (SD). Differences between the LN and OB groups 
were assessed by two-tailed unpaired Student’s t-test. Gene expression levels were logarithmically 
transformed because of their non-normal distribution. For n values below 10 per group, the non-
parametric Kruskal-Wallis test, followed by U Mann-Whitney’s pairwise comparisons were 
applied. The normal distribution of the other variables was adequate for the use of parametric tests. 
Pearson’s correlation coefficients (r) were used to analyse the association between variables. 
Multivariate linear regression analyses were conducted for the dependent variable NAMPT, 
including the parameters which showed a significant correlation with these markers as independent 
variables. The calculations were performed using the SPSS/Windows version 15.0 statistical 
package (SPSS, Chicago, IL). A P value < 0.05 was considered statistically significant. 
 
RESULTS 
Patient characteristics and metabolic profile 
The biochemical and hormonal characteristics of the subjects included in the study regarding 
the circulating concentrations and gene expression levels are shown in Tables 1 and 2, 
respectively. As expected, obese patients showed significantly higher BF (P < 0.0001) and WHR (P 
< 0.0001) as compared to the LN volunteers. Obese patients exhibited lower insulin sensitivity than 
LN individuals as evidenced by the higher HOMA (P < 0.01) and lower QUICKI (P < 0.001) 
indices. Circulating concentrations of triglycerides were significantly increased in OB patients (P < 
0.05), whereas HDL-cholesterol was reduced (P < 0.01). Circulating levels of the inflammatory 
markers CRP (P < 0.05), fibrinogen (P < 0.001), and vWF (P < 0.05) were increased in OB patients 
compared to LN subjects as the concentration of the hepatic enzyme ALT (P < 0.001), As expected, 
the high BF values were accompanied by high leptin concentrations (P < 0.0001). 
 
 
Circulating and gene expression levels of NAMPT in PBC are elevated in human obesity 
Circulating concentrations of NAMPT were significantly increased (P = 0.002) in OB patients 
compared to LN subjects (Fig.1A). Moreover, a positive correlation was found between circulating 
NAMPT levels and both BMI (r = 0.31; P = 0.044) and WHR (r = 0.47; P = 0.012) (Table 3). 
Real-time PCR analysis indicated that the mRNA expression of NAMPT in PBC followed the 
same pattern, being significantly higher (P = 0.013) in OB subjects compared to LN controls (Fig. 
1B). A positive correlation between NAMPT gene expression levels and BMI (r = 0.50; P = 
0.009), BF (r = 0.48; P = 0.014) and WHR (r = 0.43; P = 0.032) was detected (Table 3). No 
differences (P = 0.387) in omental adipose tissue gene expression levels of NAMPT between LN 
and OB subjects were observed (Fig. 1C). Although a tendency towards a decreased NAMPT gene 
expression was evident in liver biopsies of obese T2DM patients compared to obese NG subjects, it did 
not reach statistical significance (NG: 1.00 ± 0.28, T2DM: 0.66 ± 0.41 arbitrary units; P = 0.330). 
Gene expression levels of NAMPT in PBC of obese subjects were significantly increased compared 
to omental adipose tissue (P = 0.029) or liver expression (P = 0.029) (Fig. 1D). Moreover, no 
significant associations between NAMPT circulating levels and gene expression in PBC (r = 0.24; P = 
0.244), omental adipose tissue (r = 0.03; P = 0.881) or liver (r = 0.43; P = 0.212) were detected. 
 NAMPT levels and glucose metabolism 
NAMPT circulating levels were positively correlated with glucose concentrations (r = 0.33; P = 
0.049) although the association was lost after BMI adjustment (Table 3). Analogously, a positive 
correlation between gene expression levels of NAMPT in PBC and insulin concentrations (r = 0.54; 
P = 0.014) as well as the HOMA index (r = 0.59; P = 0.016) was observed. However, these 
associations were also lost after BMI adjustment (Table 3). 
 
NAMPT levels and hepatic profile 
A significant positive correlation (P < 0.01) was found between plasma NAMPT concentrations and 
ALT, AST and y-GT levels (Table 3). Moreover, the association of circulating levels of NAMPT 
with BMI or WHR was lost after adjusting for ALT, AST, ALP or y-GT (data not shown). NAMPT 
gene expression levels in PBC were positively correlated (P < 0.05) with ALP and y-GT with the 
correlation being maintained after BMI adjustment (Table 3). Furthermore, hepatic gene expression 
levels of NAMPT were positively associated (P < 0.01) with AST and ALT concentrations after 
BMI adjustment. 
 
NAMPT levels and inflammation 
Inflammation may be a possible mechanism whereby hepatic enzyme concentrations are elevated. 
Circulating NAMPT and gene expression levels in PBC were positively correlated with the 
inflammatory markers CRP (P < 0.05), fibrinogen (P < 0.05) and vWF (P < 0.05), although the 
associations were lost after BMI adjustment (Table 3). In addition, a positive correlation between 
NAMPT and HIF1 « mRNA expression levels in PBC was found (r = 0.51; P = 0.011), remaining 
statistically significant after BMI adjustment (r = 0.45; P = 0.030). No association between gene 
expression levels of NAMPT and HIF1-« in omental adipose tissue as well as liver were observed 
(data not shown). 
 
NAMPT levels and lipid metabolism 
 
Circulating concentrations of NAMPT were positively correlated with triglycerides (P < 0.05), 
total-cholesterol (P < 0.001) and LDL-cholesterol (P < 0.001) (Table 3). In order to better 
characterise the relationship between circulating levels of NAMPT and lipid metabolism as well as 
to find out which variables better predict it, multivariate linear regression analysis was 
performed, including CRP concentrations in the model due to their significant association with 
the dependent variable NAMPT. The model that best predicted NAMPT levels explained 35.6% 
of its variability (Table 4). Total-cholesterol (P Z 0.016), HDLcholesterol (P Z 0.036) and triglycerides 
(P Z 0.050) were significant independent determinants of NAMPT, suggesting a more pronounced 
influence of lipid metabolism on NAMPT circulating levels than inflammation. NAMPT gene 
expression levels of PBC were positively correlated with triglyceride concentrations (r = 0.49; P 
= 0.033) with the association being maintained after BMI adjustment (r = 0.44; P = 0.043) (Table 
3). 
DISCUSSION 
Adipose tissue acts as an active paracrine and endocrine organ, secreting a pleiad of adipokines that 
participate in diverse metabolic processes. In this sense, NAMPT has been described as an 
adipokine with complex biological effects although its mechanisms of action are still incompletely 
understood. The main findings of this study are: (1) that NAMPT circulating concentrations and 
mRNA expression levels in PBC are increased in obese patients, and (2) that plasma NAMPT levels 
are related to inflammation, lipid metabolism and hepatic enzymes suggesting a potential 
involvement in fatty liver disease. 
We detected increased circulating concentrations of NAMPT in obese patients as well as a positive 
association with BMI and WHR, which is in agreement with previous [14,20], but not all [24,25] 
data. In this sense, qualitative and quantitative discrepancies in the detection of NAMPT by EIA, 
RIA and ELISA immunoassays have been described, trying to explain the conflicting observations as 
regards the putative alterations of circulating NAMPT in human obesity. It has been suggested that 
ELISA is the most specific and applicable assay for NAMPT detection in human serum [44]. We 
measured circulating NAMPT by a commercial ELISA assay that recognised the full-length protein, 
since the importance of the detection of full-length NAMPT rather than the carboxy-terminal 
NAMPT to clarify the physiological role of this protein has been recently described [45]. To date, 
most clinical studies have used a competitive assay that recognizes the carboxy-terminal of the 
visfatin protein. In these studies, the reported concentrations of circulating visfatin have shown 
marked variability, ranging from 1 to 50 ng/ml. Indeed, it has been suggested that the C-terminal 
assay measures recombinant full-length human visfatin in a range around 100-200-fold lower than 
the true values [45]. These data support recent suggestions that this assay is compromised by 
interference with a high molecular weight compound. The dimerization of visfatin may have 
functional implications, particularly in regard to its NADþ biosynthetic enzyme function that has 
been shown to depend on dimerization and to be active also in the extracellular space [44]. Our study 
provides evidence that obese patients exhibit upregulated NAMPT mRNA expression levels in PBC, 
contrasting with previously published results where a negative or no correlation with BMI was 
detected [39,46]. However, a positive correlation has been shown with waist circumference 
measures, a better indicator of visceral obesity [46]. The lack of association between the circulating 
concentrations and the mRNA expression levels of NAMPT in PBC, omental adipose tissue and liver 
suggests that other organs or cell types, including bone marrow or muscle [11], may be contributing 
to the increased NAMPT levels in obesity. Noteworthy, accumulation of PBC at sites of 
inflammation may play a significant role in the secretion of NAMPT. Further research will provide 
more insight into the still unclear topic of the main source of increased NAMPT in human obesity. 
Although a potential relationship between NAMPT and glucose homeostasis has been previously 
suggested [13,21], no significant correlation between NAMPT concentrations and variables of insulin 
sensitivity, including fasting insulin and glucose concentrations have been described by other 
authors [14,24,25]. Furthermore, Revollo et al. reported that they were unable to reproduce the 
insulin-mimetic activity of this protein, stimulation of glucose uptake, and the glucose-lowering 
effect in vivo [16]. In line with these studies, our data suggest that NAMPT may not play a major 
role in the control of glucose homeostasis given the lack of association with plasma glucose and 
insulin after BMI adjustment. 
Dyslipidaemia is an important component of the metabolic syndrome. We have found a positive 
association between circulating NAMPT levels and triglycerides, totaland LDL-cholesterol 
suggesting a role of NAMPT in lipid homeostasis. In line with this observation, a role of NAMPT in 
lipid metabolism has been put forward due to its strong correlation with serum triglycerides 
independently of age and BF [47,48] and with total- and LDL-cholesterol [49]. Contrarily, plasma 
NAMPT levels have been associated with a high HDL-cholesterol/low triglyceride plasma lipid 
profile [50]. The different results obtained might be explained by the non-fasting samples used in the 
latter study. Recent work has shown that NAMPT may be connected with the lipid profile through 
NAD metabolism given its extra- and intra-cellular NAD biosynthetic properties. It has been shown 
that nicotinic acid increases HDL-cholesterol and also reduces triglyceride-rich lipoproteins [51]. In 
our study, the elevated concentrations of NAMPT may reflect a compensatory mechanism in order to 
reduce triglyceride accumulation. However, the role of NAMPT in lipid metabolism remains to be 
fully disentangled. 
The present study shows that increased NAMPT levels are accompanied by high concentrations 
of ALT, AST and g-GT, which are commonly increased in obese patients in relation to fatty liver 
disease. The elevated concentrations of hepatic enzymes exhibited by the obese patients may be 
influencing NAMPT concentrations or, conversely, NAMPT may be exerting an effect on the 
concentrations of the liver enzymes. In this sense, the protective role of NAMPT in non-alcoholic 
fatty liver disease (NAFLD) [52] and its involvement in portal inflammation in NAFLD patients 
has been recently reported [53]. NAD is a coenzyme with important roles in a variety of biological 
processes in part through the activation of sirtuin-1, a NAD(þ)-dependent histone deacetylase 
involved in the control of metabolic processes [54]. It has been recently suggested that an increase 
of sirtuin-1 exerts protective effects against the development of NAFLD in rats [55] and alcoholic 
liver steatosis in mice [56], suppressing the expression of genes encoding lipogenic enzymes and 
preventing lipid accumulation in the liver. 
Chronic low-grade inflammation constitutes a mediator in the development of obesity-related 
diseases. The association of NAMPT with other inflammatory markers, such as MCP-1 and PAI-1 
antigen [57] together with its increased production and release by macrophages [28,58] supports its 
pro-inflammatory properties [59]. Furthermore, a strong association between NAMPT and TNF-a 
and IL-8 in PBC has been described [39,46,58]. However, Varma et al. [19] found a negative 
association between NAMPT and CD68 as well as TNF-a in adipose tissue, suggesting an anti-
inflammatory role for NAMPT. We herein provide evidence for an association of NAMPT with 
CRP and fibrinogen, well-established markers of chronic inflammation. These acute phase proteins 
are released by the liver suggesting a hepatic response to inflammation rather than a systemic 
inflammatory process as indicated by the pattern of cytokine release. In agreement with previous 
results performed in 3T3-L1 adipocytes and MCF-7 cells [60,61], we found that gene expression of 
NAMPT in PBC in vivo, was positively correlated with HIF1-« mRNA expression in humans, a 
wellcharacterized key regulator of the adaptive response to low oxygen tension present in the 
obesity-associated inflammation state [34,62,63]. Taken together, these associations may 
contribute to the role of NAMPT in the obesity-associated inflammatory state, which takes place in 
the obesity-related cardiovascular derangements. 
In summary, we show that NAMPT circulating concentrations and gene expression levels in 
human PBC are increased in obese patients. Moreover, the association of NAMPT with 
triglycerides, hepatic enzymes and proinflammatory markers suggest an involvement in the 
dyslipidemia, fatty liver disease and low-grade chronic inflammation accompanying obesity. 
Further studies to better understand the complex implication of this adipokine in obesity and 
obesity-associated cardiovascular diseases are warranted. 
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Table 1 Anthropometric and biochemical characteristics of subjects included in the 
study of circulating concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Lean Obese P 
n (Female, male) 14 (13,1) 30 (24,6)  
Age (years) 35 ± 11 40 ± 11 0.140 
BMI (kg/m2) 20.4 ± 2.2 46.4 ± 8.0 <0.0001 
Body fat (%) 26.4 ± 5.9 51.1 ± 7.2 <0.0001 
WHR 0.75 ± 0.04 0.95 ± 0.07 <0.0001 
Fasting glucose (mmol/l) 4.8 ± 0.6 6.2 ± 2.4 0.010 
2h OGTT glucose (mmol/l) 6.0 ± 1.2 9.1 ± 4.6 0.151 
Fasting insulin (pmol/l) 46.9 ± 6.3 158.9 ± 65.8 <0.0001 
2h OGTT insulin (pmol/l) 73.5 ± 11.9 678.3 ± 357.7 <0.0001 
HOMA 1.5 ± 0.9 6.9 ± 5.2 <0.0001 
QUICKI 0.374 ± 0.041 0.301 ± 0.027 <0.0001 
Triglycerides (mmol/l) 0.75 ± 0.25 1.86 ± 0.40 0.040 
Cholesterol (mmol/l) 4.64 ± 0.65 5.00 ± 0.85 0.181 
LDL-cholesterol (mmol/l) 2.68 ± 0.72 3.21 ± 0.77 0.053 
HDL-cholesterol (mmol/l) 1.77 ± 0.58 1.09 ± 0.24 <0.001 
Leptin (ng/ml) 8.5 ± 4.3 60.9 ± 26.1 <0.0001 
Uric acid (mmol/l) 0.23 ± 0.03 0.33 ± 0.05 <0.0001 
CRP(mg/l) 1.1 ± 0.9 7.3 ± 5.3 <0.0001 
Fibrinogen (mmol/l) 2.08 ± 0.64 3.51 ± 0.5 <0.0001 
vWF (%) 81 ± 53 127 ± 49 0.012 
Homocysteine (µmol/l) 6.3 ± 1.3 8.2 ± 3.3 0.057 
ALT (UI/l) 7 ± 2 32 ± 18 <0.0001 
AST (UI/l) 12 ± 3 17 ± 6 0.017 
ALP (UI/l) 90 ± 20 110 ± 30 0.036 
γ-GT (UI/l) 10 ± 6 30 ± 31 0.007 
ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; 
BMI, body mass index; CRP, C-reactive protein; γ-GT, γ-glutamyltransferase; HOMA, homeo-
static model assessment; OGTT, oral glucose tolerance test; QUICKI, quantitative insulin 
sensitivity check index; vWF, von Willebrand factor; WHR, waist-to-hip ratio. Data are mean ± 
SD. Differences between groups were analysed by twotailed unpaired Student’s t-test. 
 
 
 
 
Table 2 Anthropometric and biochemical characteristics of subjects included in the gene 
expression study. 
 Lean Obese P 
n (Female, male) 8 (8,0) 18 (12,6)  
Age (years) 33 ± 13 43 ± 12 0.069 
BMI (kg/m2) 19.7 ± 2.0 44.9 ± 7.9 <0.0001 
Body fat (%) 26.5 ± 4.8 49.3 ± 8.3 <0.0001 
WHR 0.74 ± 0.04 0.95 ± 0.08 <0.0001 
Fasting glucose (mmol/l) 4.6 ± 0.7 6.5 ± 3.1 0.113 
Fasting insulin (pmol/l) 47.0 ± 25.2 157.8 ± 65.5 <0.0001 
HOMA 1.3 ± 1.0 8.5 ± 6.1 0.005 
QUICKI 0.386 ± 0.044 0.290 ± 0.023 <0.001 
Triglycerides (mmol/l) 0.73 ± 0.27 2.59 ± 0.59 0.062 
Cholesterol (mmol/l) 4.58 ± 0.67 5.10 ± 0.89 0.185 
LDL-cholesterol (mmol/l) 2.22 ± 0.41 3.06 ± 0.87 0.032 
HDL-cholesterol (mmol/l) 2.07 ± 0.65 1.17 ± 0.31 <0.001 
Leptin (ng/ml) 8.6 ± 4.9 57.9 ± 23.2 <0.0001 
Uric acid (mmol/l) 0.25 ± 0.03 0.35 ± 0.07 0.004 
CRP (mg/l) 0.6 ± 0.3 7.4 ± 2.6 0.032 
Fibrinogen (mmol/l) 1.90 ± 0.15 3.36 ± 0.53 <0.001 
vWF (%) 61 ± 23 123 ± 43 0.003 
Homocysteine (µmol/l) 6.6 ± 1.6 10.2 ± 3.8 0.028 
ALT (UI/l) 6 ± 2 33 ± 20 <0.001 
AST (UI/l) 13 ± 3 17 ± 6 0.145 
ALP (UI/l) 86 ± 23 101 ± 25 0.171 
γ-GT (UI/l) 12 ± 7 38 ± 12 0.070 
 
ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; 
BMI, body mass index; CRP, C-reactive protein; γ-GT, γ-glutamyltransferase; HOMA, homeo-
static model assessment; OGTT, oral glucose tolerance test; QUICKI, quantitative insulin 
sensitivity check index; vWF, von Willebrand factor; WHR, waist-to-hip ratio. Data are mean ± 
SD. Differences between groups were analysed by twotailed unpaired Student’s t-test. 
 
 
 
Table 3 Univariate analysis of the correlation between NAMPT circulating concentrations 
and mRNA NAMPT expression levels in peripheral blood cells with other variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unadjusted BMI Adjusted NAMPT circulating 
concentrations 
r P r P 
BMI 0.31 0.044 -  
WHR 0.47 0.012 0.50 0.008 
Glucose 0.33 0.049 0.29 0.129 
Triglycerides 0.42 0.011 0.38 0.025 
Cholesterol 0.51 <0.001 0.48 0.004 
LDL-cholesterol 0.53 <0.001 0.47 0.006 
C-reactive protein 0.35 0.042 0.21 0.234 
Fibrinogen 0.33 0.047 0.16 0.352 
Uric acid 0.47 0.006 0.38 0.034 
ALT 0.49 0.002 0.41 0.013 
AST 0.45 0.005 0.41 0.014 
γ-GT 0.45 0.006 0.41 0.014 
PBC NAMPT mRNA 
expression 
r P r P 
BMI 0.50 0.009 - - 
Body fat 0.48 0.014 0.11 0.614 
WHR 0.43 0.032 0.15 0.483 
Insulin 0.54 0.014 0.34 0.155 
HOMA 0.59 0.016 0.47 0.074 
Triglycerides 0.49 0.033 0.44 0.043 
Fibrinogen 0.48 0.039 0.16 0.513 
vWF 0.59 0.013 0.44 0.088 
ALP 0.52 0.020 0.49 0.050 
γ-GT 0.50 0.031 0.45 0.058 
mRNA HIF1-α 0.51 0.011 0.45 0.030 
 
 
 
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
BMI, body mass index; γ-GT, γ-glutamyltransferase; HIF1-a, hypoxia-inducible factor-1-a; 
HOMA, homeostatic model assessment; PBC, peripheral blood cells; vWF, von Willebrand 
factor; WHR, waist-to-hip ratio. Statistical significant values are in bold. 
 
Table 4 Multiple regression analysis with total-cholesterol, HDL-cholesterol LDL-
cholesterol, triglycerides and CRP as independent variables. 
 
NAMPT circulating concentrations 
r2 = 0.356; P = 0.004 β P 
Total-cholesterol 1.08 0.016 
HDL-cholesterol -0.66 0.036 
LDL-cholesterol -0.59 0.183 
Triglycerides 0.37 0.050 
CRP -0.38 0.135 
 
CRP, C-reactive protein; NAMPT, nicotinamide phosphoribosyltransferase. 
Statistical significant values are in bold. 
 
 
 
 
  
 
 
 
 
 
  
* 
 
 
 
 .  
Figure 1  
 (A) Circulating concentrations of 
NAMPT of lean (LN) and obese (OB) 
volunteers. Bars represent the mean f 
SD. Differences between groups were 
analysed by two-tailed unpaired 
Student’s t-test. **P < 0.01 vs LN. 
LN: n= 14; OB: n= 30.  
(B) Real-time PCR analysis of 
NAMPT transcript levels in 
peripheral blood cells (PBC) of lean 
(LN) and obese (OB) subjects. Bars 
represent the mean f SD of the ratio 
between gene expression to 18S 
rRNA. The expression level in lean 
subjects was assumed to be 1. 
Differences between groups were 
analysed by two-tailed unpaired 
Student’s t-test. *P < 0.05 vs LN. LN: 
n = 8; OB: n = 18.  
dent’s t-test. LN: n = 5; 
OB: n = 18.  
d using 
the Kruskal-Wallis test, followed by U Mann-Whitney’s pairwise comparisons. n = 4 per group. 
(C) Real-time PCR analysis of 
NAMPT transcript levels in omental 
adipose tissue of lean (LN) and obese 
(OB) subjects. Bars represent the 
mean f SD of the ratio between gene 
expression to 18S rRNA. The 
expression level in lean subjects was 
assumed to be 1. Differences between 
groups were analysed by two-tailed 
unpaired Stu
(D) Real-time PCR analysis of 
NAMPT transcript levels in 
peripheral blood cells (PBC), omental 
adipose tissue (OM) and liver (LV) of 
obese subjects. Bars represent the mean f SD of the ratio between gene expression to 18S rRNA. 
The expression level in PBC was assumed to be 1. Differences among groups were analyse
